Evaluating human induced pluripotent stem cell-derived cardiomyocytes for commercial drug testing

The cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high attrition rate in clinical development caused by cardiotoxicity. Since the recent discovery of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs), it has been developed as a novel,...

Full description

Bibliographic Details
Main Author: Katili, Puspita Anggraini
Format: Thesis (University of Nottingham only)
Language:English
Published: 2020
Subjects:
Online Access:https://eprints.nottingham.ac.uk/60613/

Similar Items